Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMETM) - Zinman, B; Inzucchi, S E; Lachin, J M (Cardiovascular Diabetology, 2014)
et al